Deal title

Principal
company

Partner
company

Total projected at signing (US$M)

Start date

July

Alnylam and 23andme to offer 23andme health + ancestry kits to relatives of customers with TTR-related hereditary amyloidosis

23andme Inc.

Alnylam Pharmaceuticals Inc.

Payment unspecified

7/16/19

3P to manufacture Toleranzia's TOL-2 for preclinical and clinical studies

3P Biopharmaceuticlas SL

Toleranzia AB

Payment unspecified

7/2/19

Acerus Pharmaceuticals amended and restated the exclusive agreement with Aytu Bioscience for the commercialization of Natesto in the U.S. to move the partnership from an out-license model to a co-promotion arrangement extending to 2027

Acerus Pharmaceuticals Corp.

Aytu Bioscience Inc.

Payment unspecified

7/29/19

AD Pharma to fund the development and commercialization of Acura Pharmaceuticals' LTX-03 against pain

Acura Pharmaceuticals Inc.

Abuse Deterrent Pharmaceutical LLC

$21.30

7/2/19

Adamis and Kaleo to settle patent infringement of Adamis' Zimhi naloxone product and Symjepi trademark

Adamis Pharmaceuticals Corp.

Kaleo Inc.

Payment unspecified

7/18/19

Innovation to develop and commercialize Alfasigma's brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis

Alfasigma SpA

Innovation Pharmaceuticals Inc.

$24.00

7/22/19

Alkermes and Amneal to settle patent litigation related to Vivitrol in the U.S.

Alkermes plc

Amneal Pharmaceuticals Inc.

Payment unspecified

7/29/19

Genesis to commercialize Alnylam Pharmaceuticals' Onpattro against hereditary ATTR amyloidosis in 12 countries

Alnylam Pharmaceuticals Inc.

Genesis Pharma SA

Payment unspecified

7/30/19

Cristalia to develop and commercialize Alteogen's ALT-P1 for growth disorders

Alteogen Inc.

Cristalia

$42.40

7/31/19

Cipla Gulf to commercialize Alvotech's AVT-02 in selected emerging markets for autoimmune diseases

Alvotech Swiss AG

Cipla Gulf FZ LLC

Payment unspecified

7/29/19

Aptus Clinical to design phase I/II clinical study for Valirx's VAL-301 for endometriosis

Aptus Clinical Ltd.

Valirx plc

Payment unspecified

7/4/19

Arbutus to sell its remaining royalty interest of Onpattro for hereditary transthyretin-mediated amyloidosis to Omers

Arbutus Biopharma Corp.

Omers

$20.00

7/2/19

Aridis to grant option rights of AR-301, AR-105, AR-101 and AR-201 with MabIgx technology to Serum for bacterial infections worldwide, excluding few territories

Aridis Pharmaceuticals Inc.

Serum International BV

$43.50

7/16/19

Jiangsu Wanbang to commercialize Aucta's vigabatrin for central nervous system disorders in China

Aucta Pharmaceuticals Inc.

Jiangsu Wanbang Biochemical Pharmaceutical Co. Ltd.

Payment unspecified

7/25/19

Aurigene to discover and develop small molecules against cancer for Exelixis worldwide

Aurigene Discovery Technologies Ltd.

Exelixis Inc.

$498.40

7/31/19

Avid Bioservices to provide manufacturing services to undisclosed pharmaceutical company to develop drugs

Avid Bioservices Inc.

Undisclosed

Payment unspecified

7/8/19

Kiss Industries to formulate and sell Axim Biotechnologies' chewing gum containing cannabinoids in the U.S. and Mexico

Axim Biotechnologies Inc.

Kiss Industries

Payment unspecified

7/9/19

Bayer and BMS to evaluate the combination of Stivarga and Opdivo against micro-satellite stable metastatic colorectal cancer

Bayer AG

Bristol-Myers Squibb Co.

Payment unspecified

7/18/19

Be The Match to support clinical trials of Tmunity's T cell immunotherapies against solid tumor and hematological cancer using Matchsource supply chain software

Be The Match Biotherapies

Tmunity Therapeutics Inc.

Payment unspecified

7/9/19

Sun Pharmaceutical to develop Luzhu Biotechnology's K-3 for psoriasis, rheumatoid arthritis, ankylosing spondylitis and K-11 for cancer

Beijing Luzhu Biotechnology Co. Ltd.

Beijing Science Sun Pharmaceutical Co. Ltd.

$1.22

7/24/19

Adamis to use Belcher's patents for Adamis' Symjepi as part of patent litigation settlement worldwide

Belcher Pharmaceuticals Inc.

Adamis Pharmaceuticals Corp.

Unknown

7/24/19

Genmab to develop and commercialize Blink's CD47 antibodies using Duobody platform against cancer 

Blink Biomedical SAS

Genmab A/S

$202.25

7/12/19

Brammer Biopharmaceuticals to manufacture Amicus Therapeutics' intrathecal adeno-associated virus Batten disease gene therapy programs

Brammer Biopharmaceuticals LLC

Amicus Therapeutics Inc.

Payment unspecified

7/1/19

Boehringer and Bridge Biotherapeutics to develop BBT-877 against fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis worldwide

Bridge Biotherapeutics Inc.

Boehringer Ingelheim International GmbH

$1,286.52

7/18/19

Ra Pharmaceuticals to develop and commercialize zilucoplan long acting formulation using Camurus's Fluidcrystal technology worldwide

Camurus AB

Ra Pharmaceuticals Inc.

$71.50

7/16/19

Chimerix to develop and commercialize Cantex Pharmaceuticals' CX-01 for acute myeloid leukemia worldwide

Cantex Pharmaceuticals Inc.

Chimerix Inc.

$617.50

7/26/19

Cediprof to distribute Lannett's Levothyroxine sodium tablets in the U.S., excluding Puerto Rico and the Virgin Islands

Cediprof Inc.

Lannett Co. Inc.

$20.00

7/3/19

Celltrion and Nan Fung to establish a joint venture, Vcell Healthcare Ltd. to develop and commercialize CT-P13, CT-P10 and CT-P6 in China

Celltrion Inc.

Nan Fung Group Holdings Ltd.

Payment unspecified

7/18/19

Kyowa to produce monoclonal antibodies using Chiome's technology platform

Chiome Bioscience Inc.

Kyowa Kirin

Payment unspecified

7/29/19

Cipla EU and Jiangsu Acebright to set up a joint venture in China to manufacture local respiratory products

Cipla Europe NV

Jiangsu Acebright Pharmaceutical Co. Ltd.

Unknown

7/16/19

Aura Biosciences to use Clearside's Suprachoroidal space microinjector for delivery of therapeutics against ocular cancers worldwide

Clearside Biomedical Inc.

Aura Biosciences Inc.

Payment unspecified

7/9/19

Clover Therapeutics and Genentech to conduct research on genetics of ocular diseases

Clover Therapeutics

Genentech Inc.

Payment unspecified

7/10/19

Convelo and Genentech to discover and develop remyelinating therapies for neurological disorders, including multiple sclerosis worldwide

Convelo Therapeutics Inc.

Genentech Inc.

Payment unspecified

7/16/19

CVS Caremark to distribute Titan Pharmaceuticals' Probuphine implant for opioid use disorder in the U.S.

CVS Caremark

Titan Pharmaceuticals Inc.

Payment unspecified

7/9/19

Upsher-Smith acquires assets of Zembrace and Tosymra from Dr. Reddy's in the U.S.

Dr. Reddy's Laboratories Ltd.

Upsher-Smith Laboratories Inc.

$110.50

7/23/19

Gilead Sciences to develop and commercialize Durect's HIV product using Saber technology

Durect Corp.

Gilead Sciences Inc.

$320.00

7/22/19

Confo Therapeutics and Dynabind to discover undisclosed G protein-coupled receptor modulating compounds worldwide

Dynabind GmbH

Confo Therapeutics NV

Payment unspecified

7/3/19

Egeen to conduct clinical phase IIb trial of Cyxone's rabeximod against rheumatoid arthritis in select Eastern European countries

Egeen Inc.

Cyxone AB

Payment unspecified

7/19/19

Exscientia and Rallybio to form joint venture for the discovery of small molecule therapeutics for rare diseases using artificial intelligence drug discovery platform

Exscientia Co. Ltd.

Rallybio LLC

Payment unspecified

7/23/19

Ono to develop, manufacture and commercialize Forty's 5F9 and other antibodies against CD47 in Japan, South Korea, Taiwan and the ASEAN countries

Forty Seven Inc.

Ono Pharmaceutical Co. Ltd.

$119.80

7/10/19

Astellas to develop and commercialize Frequency's FX-322 for sensorineural hearing loss worldwide, excluding the U.S.

Frequency Therapeutics

Astellas Pharma Inc.

$625.00

7/17/19

Dionymed to distribute Fruit Slabs' cannabis portfolio against pain, anxiety and sleep disorder in Central Valley and Northern California

Fruit Slabs

Dionymed Brands Inc.

Payment unspecified

7/11/19

Gilead to develop Galapagos's GLPG-1690 for idiopathic pulmonary fibrosis, with an option to develop GLPG-1972 in the U.S. for osteoarthritis and other clinical programs outside of Europe

Galapagos NV

Gilead Sciences Inc.

$6,525.00

7/14/19

Avalon and GE Healthcare to accelerate the standardization, automation and bio-production for Chimeric antigen receptor T cell therapy, cellular immunotherapy and exosomes/extracellular vesicles based regenerative therapeutics

GE Healthcare

Avalon Globocare Corp.

Payment unspecified

7/22/19

Hikma to commercialize Gedeon Richter's cariprazine for schizophrenia in Bahrain, Egypt, Jordan, Iraq, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Sudan, Syria and United Arab Emirates

Gedeon Richter Ltd.

Hikma Pharmaceuticals plc

Payment unspecified

7/25/19

Beijing SL Pharmaceutical to advance the development of Gemphire's gemcabene for dyslipidemias in China

Gemphire Therapeutics Inc.

Beijing SL Pharmaceutical Co. Ltd.

$2.50

7/24/19

Yaopharma to acquire all stock rights of Glaxosmithkline's lamivudine tablets against infections

Glaxosmithkline plc

Yaopharma Co. Ltd.

$36.64

7/8/19

Torrent to co-market Glenmark's remogliflozin etabonate for type 2 diabetes in India

Glenmark Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

Payment Unspecified

7/11/19

Ecobrands to distribute Green Gorilla's organic hemp cannabidiol products in Europe and Scandinavia

Green Gorilla

Ecobrands AS

$10.00

7/17/19

Grupo RPH to manufacture and distribute Telix Pharmaceuticals' TLX591-Cdx for prostate cancer in Brazil

Grupo RPH Radiopharmacus SA

Telix Pharmaceuticals Ltd.

Payment unspecified

7/3/19

Wuxi Pharmatech to develop Guangdong Zhongsheng Pharmaceutical's ZSYM-011 for the treatment of diabetic macular edema

Guangdong Zhongsheng Pharmaceutical Co. Ltd.

Wuxi Pharmatech (Cayman) Inc.

Payment unspecified

7/1/19

Treat Gut and Moon Biotech to discover, develop and promote microecological drugs for ulcerative colitis

Guangzhou Treat Gut Biotech

Guangzhou Moon Biotech

Payment unspecified

7/16/19

GVK BIO to develop set of injectables for Biological E

GVK Biosciences Pvt. Ltd.

Biological E Ltd.

Payment unspecified

7/31/19

Daewoong to co-promote Lundbeck's Ebixa for Alzheimer disease in Korea

H Lundbeck A/S

Daewoong Pharmaceutical Co. Ltd.

Payment unspecified

7/12/19

Endo to commercialize Helsinn's Pracinostat for acute myeloid leukemia in Canada

Helsinn Group

Endo International plc

Payment unspecified

7/31/19

Hikma to manufacture and supply 14 essential generic medicines for Civica Rx in the U.S.

Hikma Pharmaceuticals plc

Civica Inc.

Payment unspecified

7/23/19

Roche to use Imaginab's minibody CD8 T-cell imaging agent for cancer clinical trials

Imaginab Inc.

Roche Holding AG

Payment unspecified

7/9/19

Immunoprecise Antibodies and Entos Pharmaceuticals to antibody against an immuno-oncology target using B cell select platform

Immunoprecise Antibodies Ltd.

Entos Pharmaceuticals Inc.

Payment unspecified

7/15/19

Incyte and Zai Lab to develop and commercialize INCMGA-0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan

Incyte Corp.

Zai Lab Ltd.

$77.50

7/2/19

Aum Biosciences to develop and commercialize Inflection Biosciences' IBL-302 for cancers worldwide

Inflection Biosciences Ltd.

Aum Biosciences Pte. Ltd.

Payment unspecified

7/17/19

Inscopix and Biogen to research and develop therapies for chronic pain

Inscopix

Biogen Inc.

Payment unspecified

7/15/19

Glaukos to research, develop, manufacture and commercialize Intratus' drug delivery platform for dry eye disease, glaucoma and other corneal disorders worldwide

Intratus Inc.

Biogen Inc.

Payment unspecified

7/22/19

Iontas to optimize human monoclonal antibodies for Teva's targets

Iontas Ltd.

Teva Pharmaceutical Industries Ltd.

Payment unspecified

7/29/19

Celsius to identify the predictive response biomarkers in Janssen's Vega study using single cell genomics and machine learning platform

Janssen Biotech Inc.

Celsius Therapeutics Inc.

Payment unspecified

7/9/19

Celgene to develop and commercialize Jounce' JTX-8064 for cancer worldwide

Jounce Therapeutics Inc.

Celgene Corp.

$530.00

7/22/19

Onkure to develop Kdac Therapeutics' OKI-422 against cancer 

Kdac Therapeutics Inc.

Onkure Inc.

Payment unspecified

7/23/19

LGC to manufacture Aptahem's Apta-1 for concluding toxicological studies

LGC Group

Aptahem AB

Payment unspecified

7/4/19

SQ Innovation to use Ligand's captisol technology to develop captisol-enabled furosemide formulation for edema in heart failure patients worldwide

Ligand Pharmaceuticals Inc.

SQ Innovation AG

Payment unspecified

7/8/19

Lonza to manufacture and supply Omeros' narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy

Lonza Group AG

Omeros Corp.

Payment unspecified

7/31/19

Gilead and Lyndra to develop and commercialize ultra-long-acting oral human immunodeficiency virus therapies

Lyndra Therapeutics Inc.

Gilead Sciences Inc.

Payment unspecified

7/9/19

Lysando and Aicuris to develop Artilysin based drugs for bacterial infections, including hospital-acquired pneumonia, sepsis and cystic fibrosis

Lysando AG

Aicuris Anti-infective Cures GmbH

Payment unspecified

7/9/19

Puretech Health acquires LYT-100 for the treatment of lymphatic and immunofibrotic diseases, including lymphedema from Lyticon

Lyticon LLC

Puretech Health plc

Payment unspecified

7/17/19

I-Mab to develop and commercialize Macrogenics' enoblituzumab for cancer in mainland China, Hong Kong, Macau and Taiwan

Macrogenics Inc.

I-Mab Biopharma (Shanghai) Co. Ltd.

$150.00

7/10/19

Aequus to distribute Medicom's Evolve line of dry eye products in Canada

Medicom Healthcare

Aequus Pharmaceuticals Inc.

Payment unspecified

7/29/19

Mercachem to provide services to Gotham Therapeutics for accelerated hit generation and hit-to-lead expansion for epitranscriptomic target space

Mercachem Holding BV

Gotham Therapeutics Corp.

Payment unspecified

7/17/19

Merck and Phanes to enter a memorandum of understanding to develop and manufacture biologics for solid tumors

Merck & Co. Inc.

Phanes Therapeutics

Payment unspecified

7/24/19

Novartis and Mirati to evaluate the combination of MRTX-849 and TNO-155 against solid tumors

Mirati Therapeutics Inc.

Novartis AG

Payment unspecified

7/9/19

SCM and Mitoimmune to develop therapies against intractable, inflammatory, and rare diseases using clonal mesenchymal stem cells and mitochondria technology

Mitoimmune Therapeutics Inc.

SCM Lifescience Ltd.

Payment unspecified

7/11/19

Evotec acquired assets from Ncardia to advance induced pluripotent stem cells platform

Ncardia AG

Evotec SE

Payment unspecified

7/24/19

Lannett to distribute Neolpharma's generic levothyroxine sodium tablets for thyroid deficiency in the U.S.

Neolpharma Group

Lannett Co. Inc.

$20.00

7/8/19

Ocumension to develop and commercialize Nicox's NCX-4251 for blepharitis in mainland China, Hong Kong, Macau and Taiwan

Nicox SA

Ocumension Therapeutics

$11.57

7/2/19

Nimbus expanded the collaboration with Celgene to include Hematopoietic Progenitor Kinase 1 (HPK1) program against oncology

Nimbus Therapeutics Inc.

Celgene Corp.

Payment unspecified

7/9/19

Nosopharm and Evotec to advance development of NOSO-502 for enterobacteriaceae infection and NOSO-2G for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

Nosopharm SAS

Evotec SE

Payment unspecified

7/3/19

Novamedica to manufacture Unipharm's Melaxen in Russia

Novamedica

Unipharm Inc.

Payment unspecified

7/26/19

Mundipharma to commercialize Novartis' medicines for glaucoma and external eye diseases in Taiwan

Novartis AG

Mundipharma International Corp. Ltd.

Payment unspecified

7/25/19

Recordati to acquire Novartis' Signifor, Signifor LAR and LCI-699 for Cushing's disease and acromegaly

Novartis AG

Recordati SpA

$390.00

7/12/19

Gilead to develop and commercialize Novartis' three preclinical programs and agents against three undisclosed targets for human rhinovirus, influenza and herpes viruses worldwide

Novartis AG

Gilead Sciences Inc.

$291.00

7/19/19

Pepdesign to use Numaferm's technology platform for manufacturing diabetes and obesity drugs

Numaferm GmbH

Pepdesign SIA

Payment unspecified

7/22/19

Mundipharma to commercialize Orexo's Zubsolv (buprenorphine/naloxone) for the treatment of opioid dependence in Australia and New Zealand

Orexo AB

Mundipharma Pty Ltd.

Payment unspecified

7/10/19

Desitin to distribute Orphelia's Kigabeq for infantile spasms in Germany

Orphelia Pharma SA

Desitin Arzneimittel GmbH

Payment unspecified

7/16/19

Aevi Genomic Medicine to develop and commercialize OSI Pharmaceuticals' OSI-027 for congenital lymphatic malformations worldwide

OSI Pharmaceuticals Inc.

Aevi Genomic Medicine Inc.

$0.50

7/15/19

Paragon Gene Therapy to provide development and manufacturing services for Avexis' Zolgensma for spinal muscular atrophy

Paragon Bioservices Inc.

Avexis Inc.

Payment unspecified

7/16/19

Paragon to manufacture Novavax's Nanoflu and Resvax

Paragon Bioservices Inc.

Novavax Inc.

Payment unspecified

7/31/19

Paragon Gene Therapy to provide clinical manufacturing capabilities and capacity for Amicus' multiple active preclinical lysosomal disorder programs

Paragon Gene Therapy

Amicus Therapeutics Inc.

Payment unspecified

7/2/19

Penn Pharmaceutical to manufacture and supply Zogenix's Fintepla for epilepsy

Pen Pharmaceutical Services Ltd.

Zogenix Inc.

Payment unspecified

7/17/19

Peptidream to use peptide discovery platform system technology for the identification of novel macrocyclic/constrained peptides for use as peptide-drug conjugates against multiple targets of interest selected by Novartis

Peptidream Inc.

Novartis AG

Payment unspecified

7/1/19

Shijiazhuang to register, market and distribute Peptonic Medical's Vagivital for Vaginitis in People's Republic of China

Peptonic medical AB

Shijiazhuang Yuanjia Biotechnology Co. Ltd.

$0.14

7/25/19

Asieris Meditech to develop and commercialize Photocure's Cevira for human papillomavirus induced cervical precancerous lesions worldwide

Photocure ASA

Asieris Pharmaceuticals Co. Ltd.

$250.00

7/1/19

Mundipharma to distribute, market and sell Prestige Biopharma's Tuznue in western European markets, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria

Prestige Biopharma

Mundipharma International Corp. Ltd.

Payment unspecified

7/2/19

Pharmapark to commercialize Prestige Biopharma's trastuzumab biosimilar in the Russian Federation

Prestige Biopharma Pte. Ltd.

Pharmapark LLC

Payment unspecified

7/8/19

Kappa to use Probiotix' LPLDL to address cardiovascular health in the 27 countries, largely in Europe, including Russia and Singapore

Probiotix Health Ltd.

Kappa Bioscience AS

Payment unspecified

7/1/19

Tenshindo to use Probiotix' LPLDL to address cardiovascular health in Japan

Probiotix Health Ltd.

Tenshindo Inc.

Payment unspecified

7/3/19

Pro Med to distribute Mobidiag's Amplidiag and Novodiag in African countries, including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya and Uganda

Promed Diagnostics Ltd.

Mobidiag Oy

Payment unspecified

7/1/19

Jazz Pharmaceuticals acquires Redx Pharma's pan-RAF inhibitor program for treatment of cancer

Redx Pharma plc

Jazz Pharmaceuticals plc

$206.50

7/10/19

Neurimmune to develop and commercialize AAV gene therapies using Regenxbio's NAV technology for neurodegenerative diseases worldwide

Regenxbio Inc.

Neurimmune Holding AG

Payment unspecified

7/24/19

Pfizer to use Regenxbio's intellectual property related to NAV AAV9 vector to develop and commercialize gene therapies for Friedreich's ataxia

Regenxbio Inc.

Pfizer Inc.

Payment unspecified

7/31/19

Sanara Medtech to develop and commercialize antimicrobial products using Rochal Industries' patents and pending patent applications worldwide

Rochal Industries LLP

Sanara Medtech Inc.

$3.00

7/8/19

Sanofi to acquire OTC rights to Roche's Tamiflu for marketing, scientific engagement and distribution against influenza in the U.S.

Roche Holding AG

Sanofi SA

Payment unspecified

7/23/19

Avion to develop and commercialize Romeg's Gloperba for gout in the U.S.

Romeg Therapeutics LLC

Avion Pharmaceuticals LLC

Payment unspecified

7/16/19

Salix to settle intellectual property litigation with Teva related to Apriso in the U.S.

Salix Pharmaceuticals Inc.

Teva Pharmaceutical Industries Ltd.

Payment unspecified

7/31/19

Merck to commercialize Samsung's SB-8 biosimilar for Non-small-cell lung carcinoma in Europe

Samsung Bioepis

Merck & Co. Inc.

Payment unspecified

7/19/19

Samsung to manufacture and supply UCB's anti-tau candidate for treatment progressive supranuclear palsy

Samsung Biologics Co. Ltd.

UCB SA

Payment unspecified

7/31/19

Myokardia re-acquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi for $50M upfront, with an additional $30M payable to Sanofi by June 30, 2020

Sanofi SA

Myokardia Inc.

$80.00

7/22/19

Sanofi to manufacture Opiant Pharmaceuticals' OPNT-OO4 (drinabant) for the treatment of acute cannabinoid overdose

Sanofi SA

Opiant Pharmaceuticals Inc.

Payment unspecified

7/23/19

Bayer to use Sensyne Health's clinical artificial intelligence platform for development of cardiovascular therapeutics

Sensyne Health plc

Bayer AG

$6.43

7/31/19

Servier Australia and Biocurate to sign memorandum of understanding to accelerate discovery of therapeutics and drugs

Servier Laboratories (Australia) Pty Ltd.

Biocurate Pty Ltd.

Payment unspecified

7/15/19

Kurve Technology and Seurat Therapeutics to use drug delivery device for IGF-1 for migraine prevention in adults

Seurat Therapeutics Inc.

Kurve Technology Inc.

Payment unspecified

7/2/19

AMR Centre to research, develop and manufacture Shionogi's COT-143 against Pseudomonas aeruginosa infection worldwide

Shionogi & Co. Ltd.

AMR Centre Ltd.

Payment unspecified

7/22/19

Mallinckrodt to develop and commercialize Silence's SLN-500 and with an option to up to two RNAi therapeutics against autoimmune diseases worldwide

Silence Therapeutics plc

Mallinckrodt plc

$2,104.00

7/18/19

Genentech and Skyhawk to discover, develop and commercialize small molecules for oncology and neurological diseases using Skystar technology platform worldwide

Skyhawk Therapeutics Inc.

Genentech Inc.

$2,000.00

7/16/19

Merck and Skyhawk to discover, develop and commercialize small molecules for neurological diseases and cancers using Skystar technology platform worldwide

Skyhawk Therapeutics Inc.

Merck & Co. Inc.

$600.00

7/8/19

Alfasigma USA acquires Sloan Pharma's Zelnorm for irritable bowel syndrome with constipation

Sloan Pharma

Alfasigma USA Inc.

Payment unspecified

7/8/19

Casimir to develop Soleno's diazoxide choline controlled-release tablets for Prader-Willi syndrome

Soleno Therapeutics Inc.

Casimir Inc.

Payment unspecified

7/25/19

Sosei Heptares and Genentech to discover, develop and commercialize G protein-coupled receptor modulating small molecules and/or biologics for range of diseases worldwide

Sosei Heptares

Genentech Inc.

$1,026.00

7/16/19

Spectronrx to develop, manufacture and supply Y-mabs' radiolabelled omburtamab against central nervous system tumor

Spectronrx

Y-mabs Therapeutics Inc.

Payment unspecified

7/1/19

Abzena to use Synaffix's Glycoconnect and Hydraspace technologies to develop therapies

Synaffix BV

Abzena plc

Payment unspecified

7/23/19

Syneos Health to provide commercialization services of Acerus Pharmaceuticals' Natesto in the U.S.

Syneos Health Inc.

Acerus Pharmaceuticals Corp.

Payment unspecified

7/30/19

Teva to launch Hanmi's Hialuma for pain in osteoarthritis in the U.S.

Teva Pharmaceutical Industries Ltd.

Hanmi Pharmaceutical Co. Ltd.

Payment unspecified

7/2/19

Stowe to use TGV Health's intellectual property related to Zian, an anti-microbial molecule, to develop STE-006 for various eye and ear infections

TGV Group

Harrow Health Inc.

Payment unspecified

7/29/19

Mayfield to acquire intellectual property related TGV-Health's MAY-66 against bacterial infections

TGV Group

Mayfield Pharmaceuticals Inc.

Payment unspecified

7/28/19

Cannvas to develop and commercialize True Focus' natural, nutraceutical formulations to prevent THC overconsumption

True Focus International

Cannvas Medtech Inc.

$2.99

7/30/19

Undisclosed U.S. based CMO to manufacture Leaf Pharmaceuticals' LEAF-1404 for cancer

Undisclosed

Leaf Pharmaceuticals

Payment unspecified

7/11/19

Valeo Pharma to register, distribute and market an undisclosed pharmaceutical manufacturer's low molecular weight heparin biosimilar against deep vein thrombosis and pulmonary embolism in Canada

Undisclosed international pharmaceutical manufacturer

Valeo Pharma Inc.

Payment unspecified

7/8/19

Vaxart and Janssen to evaluate oral vaccine platform for universal influenza vaccine program worldwide

Vaxart Inc.

Janssen Vaccines & Prevention BV

Payment unspecified

7/9/19

Sanofi to develop and commercialize Verastem's Copiktra for cancer in Russia and Commonwealth of Independent States, Turkey, the Middle East and Africa

Verastem Oncology Inc.

Sanofi SA

$47.00

7/25/19

Vgxi to manufacture GT-EPIC based personalized cancer therapeutics to Geneos

Vgxi Inc.

Geneos Therapeutics Inc.

Payment unspecified

7/22/19

Ewopharma to distribute Vianex's amikacin in Switzerland for bacterial infections

Vianex SA

Ewopharma AG

Payment unspecified

7/30/19

Lloyd to manufacture Viriom's Elpida and other drugs against human immunodeficiency virus infection in Indonesia

Viriom Inc.

Lloyd Laboratories Inc.

Payment unspecified

7/2/19

Morphosys to acquire option to develop and commercialize Vivoryon's small-molecule glutaminyl-peptide cyclotransferase-like inhibitors, including PQ-912 for cancer worldwide

Vivoryon Therapeutics AG

Morphosys AG

$16.85

7/8/19

Abbisko Therapeutics to develop and commercialize X4 Pharmaceuticals' mavorixafor for oncology in greater China

X4 Pharmaceuticals Inc.

Abbisko Therapeutics Co. Ltd.

Payment unspecified

7/16/19

Boehringer Ingelheim and Yuhan to develop GLP1R/FGF21R agonist for the treatment of nonalcoholic steatohepatitis and related liver diseases

Yuhan Corp.

Boehringer Ingelheim International GmbH

$870.00

7/1/19

Celgene selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the 2014 Azymetric collaboration and licensing agreement with Zymeworks

Zymeworks Inc.

Celgene Corp.

$7.50

7/17/19

August

ADC Therapeutics to use Freenome's multiomics platform to develop biomarker for relapsed or refractory diffuse large B-cell lymphoma

ADC Therapeutics Sarl

Freenome Inc.

Payment unspecified

8/26/19

Processa to develop and commercialize Akashi's HT-100 for multiple fibrotic related diseases worldwide

Akashi Therapeutics

Processa Pharmaceuticals Inc.

$122.36

8/29/19

Biotheus to obtain Alligator's antibody from Alligator-Gold platform for the creation of up to three bispecific molecules in greater China

Alligator Bioscience AB

Biotheus Inc.

$143.00

8/20/19

Fannin Innovation to develop Atrapos Therapeutics' PM-43I for asthma

Atrapos Therapeutics LLC

Fannin Innovation Studio Inc.

Payment unspecified

8/20/19

Kyowa Kirin to amend the 2006 license agreement to acquire non-oncology rights of tivozanib in Aveo territories, including the U.S. and EU

Aveo Oncology Inc.

Kyowa Kirin Co. Ltd.

$416.00

8/1/19

LEO Pharma to develop and market Bausch Health's brodalumab for psoriasis worldwide outside Europe, U.S. and Canada

Bausch Health Ireland Ltd.

LEO Pharma A/S

Payment unspecified

8/13/19

Neuropore to discover small molecule therapeutics for multiple targets, including amyotrophic lateral sclerosis using Benevolentai's artificial intelligence

Benevolentai Ltd.

Neuropore Therapies Inc.

Payment unspecified

8/5/19

Beroni and Newsouth Innovations to form joint venture, Penao Co. for the development of Penao against cancer

Beroni Group Ltd.

Newsouth Innovations Pty Ltd.

Payment unspecified

8/28/19

Vaxil to use BGN's P-Esbp macromolecule to deliver a targeted cancer therapy worldwide

BGN Technologies

Vaxil Biotherapeutics Ltd.

Payment unspecified

8/28/19

Biologics to provide pharmacy services for Bayer Healthcare's Nubeqa for non-metastatic castration-resistant prostate cancer

Biologics Inc.

Bayer Healthcare Pharmaceuticals Inc.

Payment unspecified

8/1/19

Kyongbo Pharm to commercialize Can-Fite Biopharma's piclidenoson for psoriasis in South Korea

Can-Fite Biopharma Ltd.

Kyongbo Pharm Co. Ltd.

$4.00

8/1/19

Celgene to divest Otezla and related assets to Amgen

Celgene Corp.

Amgen Inc.

$13,400.00

8/25/19

Target Group to manufacture and distribute Cgreen's True Focus in the U.S., Europe and the Caribbean as a tetrahydrocannabinol antidote

Cgreen Inc.

Target Group Inc.

$1.50

8/8/19

Regenxbio to use Clearside's SCS Microinjector to deliver AAV gene therapies, including RGX-314 against wet age-related macular degeneration, diabetic retinopathy and other conditions worldwide

Clearside Biomedical Inc.

Regenxbio Inc.

$136.00

8/29/19

Cmab Biopharma to develop and manufacture Suzhou Kintor's ascrinvacumab against cancer

Cmab Biopharma Co. Ltd.

Suzhou Kintor Pharmaceuticals Inc.

Payment unspecified

8/20/19

Cognate to manufacture Caladrius' CLBS-14 against no-option refractory disabling angina

Cognate Bioservices Inc.

Caladrius Biosciences Inc.

Payment unspecified

8/7/19

Columbia Care and Moller to develop cannabinoid-infused products to be sold worldwide, including Europe and the U.S.

Columbia Care LLC

Moller Pharma GmbH

Payment unspecified

8/30/19

Alvogen to distribute Covis Pharma's Alvesco for asthma in Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Poland, Romania, Russia and Slovakia

Covis Pharma Sarl

Alvogen Inc.

Payment unspecified

8/7/19

Mustang to use CSL Behring's cytegrity cell line to produce MB-107 for immunodeficiency

CSL Behring LLC

Mustang Bio Inc.

Payment unspecified

8/27/19

Celgene to use Darwinhealth's quantitative systems biology discovery platform to identify new targets for cancer drug development

Darwinhealth

Celgene Corp.

Payment unspecified

8/28/19

Diplomat Pharmacy and Allergy Partners to dispense in-office and in-home delivery for infusion drugs and biologics against various diseases

Diplomat Pharmacy Inc.

Allergy Partners PA

Payment unspecified

8/8/19

Calliditas to commercialize Falk Pharma's Budenofalk for all indications except orphan indications outside of liver targets in the U.S.

Dr Falk Pharma GmbH

Calliditas Therapeutics AB

$44.94

8/12/19

Innovent to develop and commercialize Eli Lilly's OXM-3 for diabetes in China

Eli Lilly and Co.

Innovent Biologics Inc.

Payment unspecified

8/21/19

Enable Injections and Genentech to develop enfuse along with multiple molecule development programs

Enable Injections Inc.

Genentech Inc.

Payment unspecified

8/21/19

Cara to use Enteris' Peptelligence to develop and commercialize Korsuva tablet for pruritis, worldwide, excluding Japan and South Korea

Enteris Biopharma Inc.

Cara Therapeutics Inc.

$8.00

8/20/19

E-Therapeutics to partner with an undisclosed pharma company to identify novel disease pathways and small molecules using its network-driven drug discovery approach for neurodegenerative disease

E-Therapeutics plc

Undisclosed

Payment unspecified

8/13/19

Evotec and Nosopharm to develop antibacterial agents against gram-negative bacteria

Evotec SE

Nosopharm SAS

Payment unspecified

8/1/19

Sanofi exercised the option to progress development of Exscientia's bispecific small-molecule project

Exscientia Ltd.

Sanofi SA

Payment unspecified

8/5/19

Ultragenyx and Genetx to develop GTX-102 for Angelman syndrome with an option to acquire Genetx

Genetx Biotherapeutics LLC

Ultragenyx Pharmaceutical Inc.

$45.00

8/14/19

Toolgen to develop Genexine's Hyleukin-7 and other pipeline clinical candidates for human papilloma virus infections, lymphopenia and advanced solid tumors

Genexine Co. Ltd.

Toolgen Inc.

Payment unspecified

8/20/19

Pfizer and GSK form a 32/68 consumer healthcare joint venture, GSK Consumer Healthcare

Glaxosmithkline plc

Pfizer Inc.

Payment unspecified

8/1/19

IPS Specials and Grow Biotech to conduct clinical trials for Columbia Care's Beneseed tablets in the U.K.

Grow Biotech plc

Columbia Care LLC

Payment unspecified

8/22/19

Novartis to develop Iconic's ICON-4 for age-related macular degeneration with an option

Iconic Therapeutics Inc.

Novartis AG

Payment unspecified

8/22/19

Abbvie to conduct phase I study to evaluate combinations of Idera's tilsotolimod, nab-paclitaxel ABBV-368 and ABBV-181 against metastatic head and neck cancer

Idera Pharmaceuticals Inc.

Abbvie Inc.

Payment unspecified

8/27/19

Immatics Biotechnologies and Celgene to develop and commercialize T-lymphocyte cell therapies for multiple cancers worldwide

Immatics Biotechnologies GmbH

Celgene Corp.

$1,590.00

8/28/19

Innovent and Shenogen Pharma to evaluate combination of Tyvyt with SNG-1005 against advanced cancer

Innovent Biologics Inc.

Shenogen Pharma Group Ltd.

Payment unspecified

8/5/19

Cyclerion Therapeutics to use Insphero's 3D Insight human liver models to evaluate praliciguat in nonalcoholic steatohepatitis and fibrotic liver disease patients

Insphero AG

Cyclerion Therapeutics Inc.

Payment unspecified

8/27/19

Hikma to acquire Insys Therapeutics' naloxone and epinephrine nasal spray

Insys Therapeutics Inc.

Hikma Pharmaceuticals plc

Payment unspecified

8/9/19

Chilion to acquire Insys' Syndros and Buprenorphine products

Insys Therapeutics Inc.

Chilion Group Holdings U.S. Inc.

$12.20

8/6/19

Nabis to distribute Integrated Cannabis' infused pre-roll line Tarantula in California

Integrated Cannabis Company Inc.

Nabis

Payment unspecified

8/27/19

Glaxosmithkline exercised its option to license Ionis' antisense medicines against chronic hepatitis B virus infection

Ionis Pharmaceuticals Inc.

Glaxosmithkline plc

$262.00

8/27/19

Ips Academia Japan to grant pluripotent stem cells related patent rights to Rheincell

Ips Academia Japan Inc.

Rheincell Therapeutics GmbH

Payment unspecified

8/5/19

Ips Academia Japan and Time Therapeutics to develop and sell therapeutic and prophylactic agents for Alzheimer's disease worldwide

Ips Academia Japan Inc.

Time Therapeutics Inc.

Payment unspecified

8/16/19

Xoma to acquire royalty rights of Janssen's clinical drug candidates

Janssen Biotech Inc.

Xoma Corp.

$2.50

8/12/19

JMI Laboratories to evaluate Motif Bio's iclaprim against Listeria monocytogenes infection

JMI Laboratories

Motif Bio plc

Payment unspecified

8/19/19

Oncology Pharma to sign a letter of intent to codevelop Kalos Therapeutics' KTH-222 worldwide for the treatment of wide variety of cancers

Kalos Therapeutics Inc.

Oncology Pharma Inc.

Payment unspecified

8/19/19

Par Pharmaceutical to acquire U.S. marketing rights for the generic version of Keryx's Auryxia in litigation settlement

Keryx Biopharmaceuticals Inc.

Par Pharmaceutical Inc.

Payment unspecified

8/5/19

Path Bioanalytics to develop Laurel therapeutics' cavosonstat to treat cystic fibrosis worldwide, excluding Asia

Laurel Therapeutics Inc.

Path Bioanalytics

Payment unspecified

8/20/19

Aevi to acquire an option to develop and commercialize Medimmune's MEDI-2338 against adult-onset Still's disease worldwide

Medimmune LLC

Aevi Genomic Medicine Inc.

$162.00

8/6/19

Onconova to conduct study to develop rigosertib using Mission Bio's Tapestri platform for targeted single-cell DNA analysis

Mission Bio Inc.

Onconova Therapeutics Inc.

Payment unspecified

8/12/19

Dexcel Pharma to commercialize Mithra's Estelle and Myring contraceptive products in Israel

Mithra Pharmaceuticals

Dexcel Pharma

Payment unspecified

8/20/19

Nanjing Hicin to develop Nerviano Medical Sciences' I111b for acute myeloid leukemia worldwide

Nerviano Medical Sciences Srl

Nanjing Hicin Pharmaceutical Co. Ltd.

$25.28

8/8/19

Italfarmaco to enter into a binding term sheet agreement with Neupharma to develop and commercialize inhaled teicoplanin for infections in cystic fibrosis patients

Neupharma Inc.

Italfarmaco SpA

Payment unspecified

8/1/19

CMSH to develop Neurelis' NRL-1 for seizure disorder in greater China

Neurelis Inc.

China Medical System Holdings Ltd.

Payment unspecified

8/20/19

Adaptimmune and Noile-Immune to develop SPEAR T-cell products using proliferation inducing and migration enhancing technology against solid tumors worldwide

Noile-Immune Biotech Inc.

Adaptimmune Therapeutics plc

$312.00

8/26/19

Pharming to develop and commercialize Novartis' CDZ-173 for activated phosphoinositide 3-kinase delta syndrome in U.S., Europe and worldwide

Novartis AG

Pharming Group NV

$20.00

8/13/19

Toolgen and Nsage to research and develop stem cell therapy

Nsage Corp.

Toolgen Inc.

Payment unspecified

8/22/19

Generex Biotechnology Corp. acquired an additional 38% of Olaregen Therapeutix Inc.

Olaregen Therapeutix Inc.

Generex Biotechnology Corp.

Payment unspecified

8/19/19

Ology to provide manufacturing and stockpiling services to PHV's Nipah vaccine

Ology Bioservices Inc.

Public Health Vaccines LLC

$9.00

8/12/19

Onco360 to dispense Karyopharm's Nubeqa for non-metastatic castration-resistant prostate cancer

Onco360

Karyopharm Therapeutics Inc.

Payment unspecified

8/2/19

Onco360 to dispense Celgene's Inrebic for myelofibrosis

Onco360

Celgene Corp.

Payment unspecified

8/16/19

Oncologie and Merck to evaluate Bavituximab in combination with Keytruda for advanced gastric or gastroesophageal cancer

Oncologie Inc.

Merck & Co Inc.

Payment unspecified

8/12/19

Oncology Supply to distribute Emmaus Life Sciences' Endari for sickle cell disease

Oncology Supply

Emmaus Life Sciences Inc.

Payment unspecified

8/28/19

Orexo and Gaia to develop and commercialize a digital therapy for improving access to opioid use disorder treatment

Orexo AB

Gaia AG

Payment unspecified

8/20/19

Pharmaceutical Product Development to conduct clinical study for Harbour Biomed's oncology and immunology therapies

Pharmaceutical Product Development LLC

Harbour BioMed

Payment unspecified

8/27/19

Janssen Products to sell and distribute Pharmamar's Yondelis and other products in the U.S. and 40 more countries

Pharmamar SA

Janssen Products Inc.

Payment unspecified

8/26/19

Presage Biosciences to evaluate Bristol-Myers Squibb's early stage oncology targets in phase 0 trials using Presage's Civo platform

Presage Biosciences Inc.

Bristol-Myers Squibb Co.

Payment unspecified

8/27/19

Huons to distribute Prestige Bio's biosimilars, including HD-204 and PBP-1502 in South Korea

Prestige Biopharma

Huons Co. Ltd.

Payment unspecified

8/28/19

Asterion to acquire Preveceutical's intellectual property related to a Sol-Gel nasal delivery system, including cannabis and cannabinoids formulations

Preveceutical Medical Inc.

Asterion Ltd.

$2.65

8/6/19

Rallybio acquires Prophylix's rare disease programs

Prophylix Pharma AS

Rallybio LLC

Payment unspecified

8/22/19

Crozet Biopharma to develop Public Health Vaccines' single dose Nipah virus vaccine

Public Health Vaccines LLC

Crozet Biopharma LLC

$10.80

8/26/19

Selecta and Asklepios to jointly develop and commercialize AAV gene therapies using Immtor platform for the treatment of rare and orphan genetic diseases

Selecta Biosciences Inc.

Asklepios Biopharmaceutical Inc.

Unknown

8/6/19

Haihe Biopharma and Junshi Biosciences to evaluate the combination of glumetinib and toripalimab for solid cancers

Shanghai Junshi Biosciences Co. Ltd.

Haihe Biopharma

Payment unspecified

8/26/19

Undisclosed company to develop and commercialize antibody-based products against solid tumors using Siamab's tumor-associated carbohydrate antigen discovery technology

Siamab Therapeutics Inc.

Undisclosed

$202.00

8/19/19

Sinotherapeutics to distribute Lannett's Posaconazole delayed-release tablets 100mg in the U.S.

Sinotherapeutics Inc.

Lannett Co. Inc.

Payment unspecified

8/28/19

ADC Therapeutics and Sophia Genetics to identify genomic markers associated with phase II clinical trial of ADCT-402 in relapsed or refractory diffuse large B-cell lymphoma patients

Sophia Genetics Sa

ADC Therapeutics Sarl

Payment unspecified

8/6/19

Sosei and Takeda to discover, develop and commercialize G protein-coupled receptor targeting small molecules and biologics worldwide with initial focus on gastrointestinal disorders

Sosei Heptares

Takeda Pharmaceutical Co. Ltd.

$1,226.00

8/5/19

AstraZeneca to purchase Sobi's priority review voucher for single new drug application or biologics license application

Swedish Orphan Biovitrum AB

Astrazeneca plc

$95.00

8/22/19

Cspc Pharmaceuticals to develop and commercialize Synermore's omalizumab biosimilar for asthma and chronic idiopathic urticaria in China, excluding Hong Kong, Macau and Taiwan

Synermore Biologics Co. Ltd.

Cspc Pharmaceuticals Group Ltd.

$8.79

8/19/19

Themis and Merck to discover and develop undisclosed vaccine candidates using virus vector-based platform

Themis Bioscience GmbH

Merck & Co. Inc.

$200.00

8/22/19

Tetra Bio-Pharma to form joint venture with Thorne to develop compounds for chronic inflammatory conditions worldwide

Thorne Research Inc.

Tetra Bio-Pharma Inc.

Payment unspecified

8/21/19

Tonix acquires Trimaran's assets related to certain pyran-based compounds, including TNX-1600 for post-traumatic stress disorder and central nervous system disorders

Trimaran Pharma Inc.

Tonix Pharmaceuticals Holding Corp.

$3.57

8/19/19

Conagen acquires Undisclosed company's fermentation-based technology for glycoproteins production

Undisclosed

Conagen Inc.

Payment unspecified

8/21/19

Vizient to award Innovative Technology Contract to Kadiri Health for helicoll to treat diabetic leg ulcer and burn wounds

Vizient Inc.

Kadiri Health LLC

Payment unspecified

8/16/19

Newsoara to develop and commercialize Zenith's ZEN-3694 for all indications, including cancer in China, Hong Kong, Taiwan, and Macau

Zenith Epigenetics Ltd.

Newsoara Biopharma Co. Ltd.

$78.00

8/6/19

Hoth to co-develop Zylo's anandamide loaded Z-pods for cutaneous lupus erythematosus

Zylo Therapeutics LLC

Hoth Therapeutics Inc.

Payment unspecified

8/21/19

September

Clovis and 3BP to discover 3B-201 and 3B-202 plus radiopharmaceuticals for three targets using 3BP's technology platform worldwide and the U.S., excluding Europe, Russia, Turkey, Israel

3B Pharmaceuticals GmbH

Clovis Oncology Inc.

$12.00

9/23/19

Adaptive Biotechnologies to use next-generation sequencing-based Clonoseq assay to assess minimal residual disease across multiple drug development programs within the Amgen hematology portfolio worldwide

Adaptive Biotechnologies Corp.

Amgen Inc.

Payment unspecified

9/17/19

Adhex Pharma to manufacture Klaria Pharma's KL-00119 against migraine for clinical registration trial

Adhex Pharma

Klaria Pharma Holding Ab

Payment unspecified

9/18/19

Adrexpharma to distribute Medipharm's cannabis concentrate derivative products in Germany

Adrexpharma GmbH

Medipharm Labs Inc.

Payment unspecified

9/24/19

Anchiano Therapeutics to acquire option rights to develop and commercialize ADT Pharmaceuticals' Pan-RAS inhibitor and PDE10/β-catenin inhibitor programs for cancer worldwide

ADT Pharmaceuticals

Anchiano Therapeutics

$3.00

9/23/19

China National Biotec Group to distribute AAT's Algeness in mainland China

Advanced Aesthetic Technologies Inc.

China National Biotec Group

Payment unspecified

9/19/19

Talem and Agonox to sign a letter of intent to form a joint venture for the development of antibody therapeutics to target T cell mediated anti-tumor activity worldwide

Agonox Inc.

Talem Therapeutics

$720.00

9/24/19

Albany Molecular Research to manufacture Translate Bio's preclinical and clinical-stage programs

Albany Molecular Research Inc.

Translate Bio MA Inc.

Payment unspecified

9/12/19

Horus expanded the agreement to distribute Alimera's Iluvien for diabetic macular edema in Belgium, the Netherlands and Luxembourg

Alimera Sciences Inc.

Horus Pharma SAS

Payment unspecified

9/12/19

Alivamab Discovery Services to provide Alivamab Mouse technology to discover and deliver antibodies for Janssen

Alivamab Discovery Services LLC

Janssen Research & Development LLC

Payment unspecified

9/16/19

Adhera Therapeutics to co-promote Allegis Pharmaceuticals' Nitrolingual Pumpspray to treat angina pectoris due to coronary artery disease

Allegis Pharmaceuticals LLC

Adhera Therapeutics Inc.

Payment unspecified

9/6/19

Generex to sign binding letter of intent to acquire 51% of Altucell

Altucell Inc.

Generex Biotechnology Corp.

Payment unspecified

9/9/19

American Cryostem and Biosolutions to conduct clinical study on Atcell for post-concussion syndrome

American Cryostem Corp.

Biosolutions Clinical Research Center LLC

Payment unspecified

9/11/19

Applied Biomath and Verseau to deliver the pharmacology, pharmacokinetic and target engagement analysis for treatment of cancer

Applied Biomath LLC

Verseau Therapeutics Inc.

Payment unspecified

9/3/19

Oxford Cannabinoid Technologies to acquire option rights to develop and commercialize Askat's CB2 receptor agonist, AAT-730

Askat Inc.

Oxford Cannabinoid Technologies

Payment unspecified

9/20/19

Theragnostics to use Astrazeneca's intellectual property rights to develop radionuclide-labelled PARP inhibitors against cancer

Astrazeneca plc

Theragnostics Ltd.

Payment unspecified

9/5/19

Atomwise and Hansoh Pharmaceutical to design and discover eleven undisclosed target proteins in multiple therapeutic areas using artificial intelligence technology

Atomwise

Hansoh Pharmaceutical Group Company Ltd.

$1,500.00

9/11/19

Atomwise and Oncostatyx to establish a joint venture to discover and develop KDM5B inhibitors for triple-negative breast cancer

Atomwise

Oncostatyx LLC

Payment unspecified

9/10/19

Atomwise and Atropos to launch joint venture for discovery of senescence modulating small molecules for cancer

Atomwise

Atropos Therapeutics Inc.

Unknown

9/11/19

Poly Pharmaceuticals to co-promote Aytu Bioscience's Tuzistra XR in the U.S.

Aytu Bioscience Inc.

Poly Pharmaceuticals Inc.

Payment unspecified

9/4/19

BC Platforms to provide clinical and genomic data management solution to Debiopharm oncology products

BC Platforms

Debiopharm SA

Payment unspecified

9/18/19

Be The Match to support clinical trials of Celyad's allogeneic CAR-T therapies for cancer

Be The Match Biotherapies

Celyad SA

Payment unspecified

9/10/19

R-Pharm to sign letter of intent to develop and commercialize Beijing Health's nonavalent HPV vaccine against HPV infections and cervical cancer in Russia

Beijing Health Guard Biotechnology Co. Ltd.

R-Pharm

Payment unspecified

9/5/19

Novartis to use Benevolentai's technology to interrogate clinical trial and experimental data for oncology assets

Benevolentai Ltd.

Novartis Pharma AG

Payment unspecified

9/5/19

Vaxil Bio to use BGN's E-selectin targeted polymer to develop and commercialize targeted cancer therapy worldwide

BGN Technologies

Vaxil Biotherapeutics Ltd.

Payment unspecified

9/23/19

Avanos to develop and commercialize Bioq Pharma's non-opioid post-operative pain pharmaceutical product in the U.S., Canada and Mexico

Bioq Pharma Inc.

Avanos Medical Inc.

Payment unspecified

9/17/19

Oncoheroes Biosciences to develop and commercialize Boehringer's volasertib for the treatment of pediatric cancer indications worldwide

Boehringer Ingelheim International GmbH

Oncoheroes Biosciences Inc.

Payment unspecified

9/16/19

Biomotiv and BMS to form and fund new companies to develop novel therapeutics against multiple diseases, with an acquisition option for BMS

Bristol-Myers Squibb Co.

Biomotiv LLC

Payment unspecified

9/4/19

Oxford Nanopore to use Caribou's CRISPR-Cas9 related intellectual property for nanopore sequencing worldwide

Caribou Biosciences Inc.

Oxford Nanopore Ltd.

Payment unspecified

9/19/19

Phio Pharmaceuticals to evaluate its self-delivering RNAi compounds to synergistically modify Carisma's chimeric antigen receptor macrophages for use in cancer

Carisma Therapeutics Inc.

Phio Pharmaceuticals Corp.

Payment unspecified

9/9/19

Catalent to manufacture Acura's LTX-03 tablets for pain

Catalent Inc.

Acura Pharmaceuticals Inc.

Payment unspecified

9/9/19

An undisclosed company to distribute Cesca Therapeutics' X-Series products worldwide, excluding China

Cesca Therapeutics Inc.

Undisclosed

$2.00

9/9/19

Clinigen to distribute Cheplapharm's Etopophos and Vepesid against cancer in Australia and New Zealand

Cheplapharm Arzneimittel GmbH

Clinigen Group plc

Payment unspecified

9/1/19

Mundipharma to develop and commercialize Cidara's intravenous rezafungin and option for subcutaneous rezafungin for fungal infections worldwide, excluding the U.S. and Japan

Cidara Therapeutics Inc.

Mundipharma International Corp. Ltd.

$615.76

9/3/19

Kalbe to sell CJ Healthcare's K-CAB for gastroesophageal reflux in Indonesia

CJ Healthcare Corp.

PT Kalbe Farma Tbk

Payment unspecified

9/18/19

Wize Pharma to develop Copernicus Therapeutics' WP-REP1, an ophthalmic nonviral gene therapy, for the treatment of choroideremia worldwide

Copernicus Therapeutics Inc.

Wize Pharma Inc.

Payment unspecified

9/4/19

Fujifilm exercised its option with Cynata Therapeutics for a worldwide license to develop and commercialize CYP-001 for graft-versus-host disease

Cynata Therapeutics Ltd.

Fujifilm Corp.

Payment unspecified

9/17/19

Dariohealth and Dance Biopharm to integrate mist smart inhaler with digital platform for chronic disease patients

Dariohealth Corp.

Dance Biopharm Inc.

Payment unspecified

9/11/19

Alexion Pharmaceuticals to develop and commercialize Eidos' AG-01 for TTR amyloidosis in Japan

Eidos Therapeutics Inc.

Alexion Pharmaceuticals Inc.

$50.00

9/9/19

Thermo Fisher to develop companion diagnostic using Oncomine test to identify RET-altered non-small-cell lung cancer and thyroid cancer patients for Eli Lilly's LOXO-292

Eli Lilly and Co.

Thermo Fisher Scientific Inc.

Payment unspecified

9/2/19

Evotec and Takeda Pharmaceutical to develop five small molecule discovery programs against oncology, gastroenterology, neuroscience and rare diseases

Evotec SE

Takeda Pharmaceutical Co. Ltd.

$850.00

9/24/19

Fujitsu and Peptidream to discover and develop peptide drugs using Digital Annealer

Fujitsu Ltd.

Peptidream Inc.

Payment unspecified

9/20/19

Futura Medical and Cbderma to form joint venture to develop Dermasys for cannabidiol delivery

Futura Medical plc

Cbderma Technology Ltd.

Payment unspecified

9/10/19

Gaba Therapeutics and Atai Life to develop GRX-917 for mood disorders, including anxiety and depression

Gaba Therapeutics

Atai Life Sciences AG

Payment unspecified

9/20/19

Adalta and GE Healthcare to develop i-bodies as diagnosis in immunotherapy

General Electric Co.

Adalta Pty Ltd.

Payment unspecified

9/16/19

DAS Therapeutics acquires GT Biopharma's GTB-004 for myasthenia gravis

GT Biopharma Inc.

DAS Therapeutics Inc.

$6.20

9/19/19

Silanes to launch Hanmi's Amosartan plus and Amosartan Q for dyslipidemia and hypertension in Latin America

Hanmi Pharmaceutical Co. Ltd.

Laboratorios Silanes SA De CV

Payment unspecified

9/11/19

Happify and Sanofi to develop digital therapeutics for multiple sclerosis worldwide

Happify Inc.

Sanofi SA

Payment unspecified

9/17/19

Blanver to commercialize Helsinn's Pracinostat for acute myeloid leukemia in South America

Helsinn Healthcare SA

Blanver Farmoquimica Ltda

Payment unspecified

9/2/19

Pacific Alliance Group to acquire a majority stake in Hisun Bioray Bio-pharmaceutical

Hisun Bioray Bio-pharmaceutical Co. Ltd.

Pacific Alliance Group

$556.97

9/4/19

Batavia to use Horizon's GS knockout CHO K1 cell line expression system to develop antibody expressing cell lines

Horizon Discovery Group plc

Batavia Biosciences BV

Payment unspecified

9/3/19

Novartis and IFM Due to research and develop cGAS/STING programs against inflammatory and autoimmune diseases, with an option to acquire IFM Due

IFM Due

Novartis AG

$840.00

9/5/19

Ildong to market Glaxosmithkline's Relenza for the treatment of influenza A and B virus infections

Il Dong Pharmaceutical Co. Ltd.

Glaxosmithkline plc

Payment unspecified

9/6/19

I-Mab Biopharma and Junshi Biosciences to evaluate the combination of TJD-5 with toripalimab to treat cancers in China

I-Mab Biopharma Co. Ltd.

Shanghai Junshi Biosciences Co. Ltd.

Payment unspecified

9/10/19

I-Mab and Merck to evaluate the combination of TJC-4 and Keytruda for multiple cancer types in a phase I clinical trial

I-Mab Biopharma Co. Ltd.

Merck & Co. Inc.

Payment unspecified

9/23/19

Adhera to use Indegene's co-commercialization model to advance the commercialization of Prestalia in the U.S.

Indegene

Adhera Therapeutics Inc.

Payment unspecified

9/10/19

Selexis to commercialize Inflamacore's IC-100 for multiple inflammatory conditions

Inflamacore LLC

Selexis SA

Payment unspecified

9/5/19

Inflammasome and Boehringer Ingelheim to develop up to three therapies using intravitreal drug delivery technology for retinal diseases

Inflammasome Therapeutics Inc.

Boehringer Ingelheim International GmbH

$160.00

9/20/19

Tris to market, sell and distribute Intellipharmaceutics' Desvenlafaxine Succinate ER in the U.S.

Intellipharmaceutics International Inc.

Tris Pharma Inc.

Payment unspecified

9/5/19

Roslin Technologies to use Ips Academia Japan's patents related to iPS cell-derived cells

Ips Academia Japan Inc.

Roslin Technologies Ltd.

Payment unspecified

9/4/19

Astrazeneca amended the agreement to obtain exclusive rights to develop, manufacture and commercialize Ironwood Pharmaceuticals' linaclotide in China

Ironwood Pharmaceuticals Inc.

Astrazeneca plc

Payment unspecified

9/16/19

Duchembio to develop and commercialize Isotopen's Solucin targeted radionuclide therapy for neuroendocrine tumors in South Korea

Isotopen Technologien München AG

Duchembio Co. Ltd.

Payment unspecified

9/2/19

Kahr Medical and Roche to evaluate the combination of DSP-107 with atezolizumab in phase I/II study to treat non-small-cell lung cancer

Kahr Medical Ltd.

Roche Holding AG

Payment unspecified

9/9/19

Kamada extended its strategic supply agreement with Takeda Pharmaceutical for Glassia through 2021, receiving royalties of 12% on net sales through August 2025 and 6% afterward until 2040

Kamada Ltd.

Takeda Pharmaceutical Ltd.

Payment unspecified

9/4/19

Healthcare Royalty Partners to purchase Karyopharm's royalty to develop and commercialize Xpovio against heavily pretreated multiple myeloma worldwide

Karyopharm Therapeutics Inc.

Healthcare Royalty Partners

$150.00

9/16/19

Boston Pharmaceuticals to develop and commercialize Kempharm's serdexmethylphenidate and d-methylphenidate based therapeutics for attention deficit and hyperactivity disorder worldwide

Kempharm Inc.

Boston Pharmaceuticals

$493.00

9/3/19

Lexicon Pharmaceuticals to receive $260M for termination of the alliance with Sanofi for development and commercialization of Zynquista

Lexicon Pharmaceuticals Inc.

Sanofi SA

$260.00

9/12/19

Huons to develop and commercialize Lipac's TSD-001 for various indications

Lipac Oncology LLC

Huons Co. Ltd.

Payment unspecified

9/16/19

Lonza to manufacture Celltrion Healthcare's Remsima for autoimmune diseases including Crohn's disease and rheumatoid arthritis

Lonza Group AG

Celltrion Healthcare Co. Ltd.

Payment unspecified

9/3/19

Cayman to use Lubrigreen Biosynthetics' patents related to fatty acid hydroxy fatty acid products

Lubrigreen Biosynthetics LLC

Cayman Chemical Co. Inc.

Payment unspecified

9/3/19

Boehringer Ingelheim and Lupin to develop and commercialize LNP-3794 and KRAS inhibitor combination drug to treat KRAS-driven cancers

Lupin Ltd.

Boehringer Ingelheim International GmbH

$720.00

9/4/19

Grunenthal to develop and commercialize Mesoblast's MPC-06-ID for chronic low back pain in Europe and Latin America

Mesoblast Ltd.

Grunenthal GmbH

$1,150.00

9/9/19

Daiichi Sankyo to commercialize Mitsubishi Tanabe's edaravone for amyotrophic lateral sclerosis in Brazil

Mitsubishi Tanabe Pharma GmbH

Daiichi Sankyo Co. Ltd.

Payment unspecified

9/17/19

Mylan to distribute Eisai's Teceris for metastatic breast cancer in India

Mylan NV

Eisai Pharmaceuticals India Pvt. Ltd.

Payment unspecified

9/20/19

Nissan and Veritas to discover small molecule drugs targeting nucleic acids

Nissan Chemical Corp.

Veritas In Silico Inc.

Payment unspecified

9/6/19

Amplyx acquired worldwide rights of Novartis' MAU-868 for BK viral disease

Novartis Pharmaceuticals Corp.

Amplyx Pharmaceuticals Inc.

Payment unspecified

9/16/19

Peptidream and JSR to identify peptides applicable to the affinity chromatography process

Peptidream Inc.

JSR Corp.

Payment unspecified

9/20/19

Hanmi Pharmaceutical to use Phanes' antibody sequences to discover and develop bi and multi-specific antibodies for oncology worldwide

Phanes Therapeutics

Hanmi Pharmaceutical Co. Ltd.

Payment unspecified

9/24/19

Pharmaceutics to manufacture and supply Sagent's generic Fulvestrant Injection 250mg/5ml against breast cancer

Pharmaceutics International Inc.

Sagent Pharmaceuticals Inc.

Payment unspecified

9/23/19

Sandoz to commercialize Polpharma Biologics' natalizumab biosimilar for relapsing-remitting multiple sclerosis worldwide

Polpharma Biologics SA

Sandoz AG

Payment unspecified

9/3/19

Bayer to use Probiogen's Glymaxx to develop undisclosed antibody candidate for oncology

Probiogen AG

Bayer AG

Payment unspecified

9/10/19

Askbio acquires Rovermed's nanotechnology cargo delivery platform assets

Rovermed Biosciences LLC

Asklepios Biopharmaceutical Inc.

Payment unspecified

9/17/19

Mindmed acquires Savant's 18-MC to treat drug addiction

Savant HWP Inc.

Mind Medicine Inc.

Payment unspecified

9/16/19

Astrazeneca to use Schrodinger's advanced computing platform to accelerate the drug discovery

Schrodinger LLC

Astrazeneca plc

Payment unspecified

9/4/19

Takeda and Schrodinger expanded the collaboration to discover multi-targets for various diseases using computational silico platform

Schrodinger LLC

Takeda Pharmaceuticals Co. Ltd.

Payment unspecified

9/5/19

Undisclosed pharmaceutical company to use Secarna's Lnaplus oligonucleotides in oncology research

Secarna Pharmaceuticals GmbH & Co. KG

Undisclosed

Payment unspecified

9/10/19

Selexis to provide cell line expression technologies to develop Zyversa's IC-100 for multiple inflammatory conditions

Selexis SA

Zyversa Therapeutics Inc.

Payment unspecified

9/5/19

Sengine and Atomwise to form joint venture to accelerate the oncology drug discovery using platform technologies

Sengine Precision Medicine Inc.

Atomwise

Payment unspecified

9/10/19

Kalbe Genexine to develop and commercialize Shanghai Henlius' HLX-10 in 10 countries

Shanghai Henlius Biotech Co. Ltd.

Kalbe Genexine Biologics

$682.00

9/12/19

Solti to conduct clinical research on Context Therapeutics' Apristor in breast cancer patients

Solti Breast Cancer Research Group

Context Therapeutics LLC

Payment unspecified

9/16/19

Soricimed and IAG to develop SOR-C13 for solid cancer tumors

Soricimed Biopharma Inc.

Image Analysis Group

Payment unspecified

9/5/19

Terrascend to commercialize Syqe Medical's Syqe Inhaler in Canada

Syqe Medical Ltd.

Terrascend Corp.

Payment unspecified

9/16/19

Genmab and Tempus to advance disease targets and biomarkers for generating treatments in oncology

Tempus Inc.

Genmab A/S

Payment unspecified

9/9/19

Terumo to manufacture Teribone 28.2 microg for Asahi Kasei Pharma to treat osteoporosis with high risk of fractures

Terumo Corp.

Asahi Kasei Pharma Corp.

Payment unspecified

9/20/19

Super-Pharm to purchase 50% stake in Teva's pharmaceutical preparations business to form a new company

Teva Pharmaceutical Industries Ltd.

Super Pharm Ltd.

Payment unspecified

9/1/19

Zymeworks to use Trianni's mouse technology to discover and develop fully human monoclonal antibodies

Trianni Inc.

Zymeworks Inc.

Payment unspecified

9/10/19

Glycotope to use Tubulis' antibody drug conjugate (ADC) technologies, Tub-tag to identify the ADC candidates

Tubulis GmbH

Glycotope GmbH

Payment unspecified

9/11/19

Antibody technology company to evaluate Scancell's pipeline of monoclonal antibodies targeting TaGs using Avidimab technology against cancer

Undisclosed

Scancell Ltd.

Payment unspecified

9/4/19

Grunenthal and Uniquest to develop non-opioid drug therapies for chronic neuropathic pain

Uniquest Pty Ltd.

Grunenthal GmbH

Payment unspecified

9/3/19

Can-Fite and Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases

Univo Pharmaceuticals Ltd.

Can-Fite Biopharma Ltd.

$0.50

9/10/19

VBI Vaccines and GSK to evaluate the combination of VBI-1901 with AS01B adjuvant in phase I/IIa clinical study against recurrent glioblastoma

VBI Vaccines Inc.

Glaxosmithkline plc

Payment unspecified

9/10/19

Alytas to use Velabs Therapeutics' microfluidic-based technology to develop immune-based therapy against obesity worldwide

Velabs Therapeutics GmbH

Alytas therapeutics GmbH

Payment unspecified

9/3/19

Widetrial further agreed to provide expanded access programs to Mateon Therapeutics to develop OT-101 for pancreatic cancer

Widetrial Inc.

Mateon Therapeutics Inc.

Payment unspecified

9/9/19

China Pharma to enter memorandum of understanding to develop World Health Advanced Technologies' Enercel in China

World Health Advanced Technologies Ltd.

China Pharma Holdings Inc.

Payment unspecified

9/11/19

X-Chem and Maruho to discover and develop compounds for novel targets against human diseases worldwide

X-Chem Inc.

Maruho Co. Ltd.

Payment unspecified

9/4/19

Flexion to develop and commercialize Xenon's XEN-402 with FX-301 for post-operative pain worldwide

Xenon Pharmaceuticals Inc.

Flexion Therapeutics Inc.

$127.75

9/9/19

Merck and Y-Trap to develop and commercialize antibody-ligand traps for cancer immunotherapy

Y-Trap Inc.

Merck KGaA

Payment unspecified

9/19/19


Notes

This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis.

 

No Comments